| Distinguishes traditional compounders and outsourcing facilities. | |
| Expedited and streamlined generic drug approvals via an ANDA or 505b2 | |
| Reduced public health risks by stopping reimportation of drugs, unless an individual brings <90 DAY supply or drug is not available in the US. | |
| FDA Amendemtns Act of 2007 |